瘦素和瘦素受体在乳腺癌组织中的表达及其与临床预后的关系  

Clinical significance and prognosis of expressions of leptin/leptin receptor in breast cancer

作　　者：陈薇[1] 查小明[2] 刘晓安[2] 张伟民[3] 殷咏梅[1] 

机构地区：[1]南京医科大学第一附属医院肿瘤科,南京210029 [2]南京医科大学第一附属医院乳腺外科,210029 [3]南京医科大学第一附属医院病理科,210029

出　　处：《临床肿瘤学杂志》2010年第6期493-497,共5页Chinese Clinical Oncology

基　　金：国家自然科学基金面上项目[30772474(BA07)];江苏省科技厅基础研究计划自然科学基金(BK2008477);人事部留学回国人员基金(2009IA09);江苏省卫生厅开放课题(XK18200904)

摘　　要：目的检测瘦素(OB)和瘦素受体(ObR)在人乳腺癌组织中的表达情况,探讨二者与HER-2以及临床病理之间的关系,并分析它们对预后的影响。方法用免疫组织化学的方法检测114例乳腺癌组织中OB和ObR的表达,回顾分析相关的临床病理资料和随访情况。结果 OB和ObR在大多数乳腺癌组织中均有表达,阳性率分别为79.8%和85.1%;OB和ObR的表达与患者的年龄、绝经状态、肿瘤大小、肿瘤病理学分型、淋巴结转移及远处转移均无关(P>0.05);与ER、PR、p53的表达状态也无关(P>0.05);ObR的表达与HER-2相关(P=0.018);OB阳性者的总生存时间(OS)短(P=0.009);在亚组分析中,绝经后、三阴乳腺癌和淋巴结转移组中OB阳性的OS均短于OB阴性(P分别为0.038、0.006和0.004)。结论 ObR与HER-2在乳腺癌中的表达具有相关性,OB可能是导致乳腺癌预后不良的因素。Objective To analyze clinicopathologic factors and prognosis of expressions of leptin（OB）/leptin receptor（ObR）in breast cancer.Methods The expression of OB and ObR was examined by immunohistochemistry in tissues of 114 breast cancer samples.Results Positive expressions of OB and ObR were noted in 79.8% and 85.1% of the samples.The expression of OB and ObR in breast cancer tissue was not significantly related to the clinicopathological characteristics,including ages,menopause,tumor size,pathological type,lymph node metastasis and distant metastasis（P〉0.05）.The expression of OB and ObR was not significantly related to ER/PR and p53 status（P〉0.05）.The expression ObR showed a significant correlation with the HER-2 status（P=0.018）.The expression of OB was significantly related to overall survival（P=0.009）.For the postmenopause patients,triple negative patients and lymph node metastasis patients,the overall survival of OB-positive group was significantly lower than that of the OB-negative group（P=0.038,P=0.006,P=0.004）.Conclusion There is a correlation between ObR and HER-2 expression in breast cancer tissues,and leptin may be a negative prognosis factor for breast cancer.

关 键 词：乳腺癌 瘦素 瘦素受体 HER-2 临床病理特征 预后 

分 类 号：R730.51[医药卫生—肿瘤]